Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Gonzalez-Lopez

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Medical Physics|July 15, 2015
Small fields measurements with radiochromic filmsAntonio Gonzalez-Lopez, Juan-Antonio Vera-Sanchez, Jose-Domingo Lago-Martin
Vaccine|April 17, 2019
Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation studyGeert Leroux-Roels, Fien De Boever, Cathy Maes, et al.
Cirugia Espanola|April 15, 2014
Differences between en bloc resection and enucleation of retroperitoneal sarcomasJosé Antonio Gonzalez Lopez, Vicente Artigas Raventós, Manuel Rodríguez Blanco, et al.
Clinical Immunology (Orlando, Fla.)|November 1, 2019
Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccineAntonio Gonzalez-Lopez, Jaap Oostendorp, Thomas Koernicke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2019
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy AdultsPaola Cicconi, Claire Jones, Esha Sarkar, et al.
Annals of Surgical Oncology|July 14, 2025
Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PEC): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)Eyal Mor, Sameer Apte, Catherine Mitchell, et al.
Vaccine|December 23, 2022
Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral responseEmilio Siena, Francesca Schiavetti, Erica Borgogni, et al.
The Journal of Infectious Diseases|December 9, 2022
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of AgeJavier Díez-Domingo, Xavier Sáez-Llorens, Miguel A Rodriguez-Weber, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
The Journal of Infectious Diseases|July 21, 2023
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized TrialXavier Sáez-Llorens, Ximena Norero, Marisa Márcia Mussi-Pinhata, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Medical Physics|July 15, 2015
Small fields measurements with radiochromic filmsAntonio Gonzalez-Lopez, Juan-Antonio Vera-Sanchez, Jose-Domingo Lago-Martin
Vaccine|April 17, 2019
Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation studyGeert Leroux-Roels, Fien De Boever, Cathy Maes, et al.
Cirugia Espanola|April 15, 2014
Differences between en bloc resection and enucleation of retroperitoneal sarcomasJosé Antonio Gonzalez Lopez, Vicente Artigas Raventós, Manuel Rodríguez Blanco, et al.
Clinical Immunology (Orlando, Fla.)|November 1, 2019
Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccineAntonio Gonzalez-Lopez, Jaap Oostendorp, Thomas Koernicke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2019
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy AdultsPaola Cicconi, Claire Jones, Esha Sarkar, et al.
Annals of Surgical Oncology|July 14, 2025
Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PEC): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)Eyal Mor, Sameer Apte, Catherine Mitchell, et al.
Vaccine|December 23, 2022
Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral responseEmilio Siena, Francesca Schiavetti, Erica Borgogni, et al.
The Journal of Infectious Diseases|December 9, 2022
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of AgeJavier Díez-Domingo, Xavier Sáez-Llorens, Miguel A Rodriguez-Weber, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
The Journal of Infectious Diseases|July 21, 2023
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized TrialXavier Sáez-Llorens, Ximena Norero, Marisa Márcia Mussi-Pinhata, et al.
Pageof 1